Keywords
immune thrombocytopenia - refractory ITP - splenectomy - thrombopoietin receptor agonists
Schlüsselwörter
Immunthrombozytopenie - therapieresistente ITP - Splenektomie - Thrombopoetin-Rezeptoragonisten
Introduction
Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by reduction
in the peripheral platelet (PLT) count below 100 × 109/L, in the absence of known factors or disorders inducing thrombocytopenia.[1]
[2] In Poland, ITP occurs with an incidence rate of 3.5 per 100,000 people per year.[3] The pathomechanism of primary ITP includes PLT destruction in the reticuloendothelial
system mediated by autoantibodies, complex autoimmune processes involving T lymphocytes,
and impaired megakaryocytopoiesis.[1]
[2]
[4]
[5]
[6] Secondary ITP can be associated with other autoimmune diseases (e.g., systemic lupus
erythematosus or rheumatoid arthritis), infections (e.g., HIV, HBV, HCV, Helicobacter pylori), or underlying immune dysregulation syndromes, such as common variable immunodeficiency.[2] According to its duration, ITP is divided into acute (<3 months), persistent (3–12
months), and chronic (>12 months).[7] ITP typically manifests with mucocutaneous bleeds, but may also be asymptomatic.
Severe bleeding manifestations such as intracranial hemorrhage and gastrointestinal
or genitourinary bleeds are relatively uncommon.[8] The primary purpose of ITP treatment is to protect patients from life-threatening
bleeding by keeping the PLT count at the hemostatic level (> 20–30 × 109/L in most cases). First-line treatment includes corticosteroids and intravenous immunoglobulins,
whereas second-line therapy usually consists of thrombopoietin receptor agonists (TPO-RAs),
rituximab, immunosuppressants, and splenectomy.[9]
Aim of the Study
The aim of the study was to characterize a group of adult ITP patients in terms of
clinical manifestation and treatment, as well as to present the current standard of
care of ITP in Poland, in the context of local and international guidelines.
Materials and Methods
The study population was identified in the tertiary reference center in Krakow, Poland
(Haematology Clinic, Jagiellonian University). We enrolled into the study consecutive
patients with ITP diagnosis, treated in our clinic between January 2006 and January
2021, identified from the patient registry. The initial number of patients was 249.
We excluded four patients with incomplete medical records. Data were obtained retrospectively
from medical documentation (both inpatient and outpatient files). At presentation,
85.7% of patients (n = 210) had already been diagnosed with ITP and had previously been treated or observed
in other centers (mean duration of previous care was 5.8 ± 7.6 years, median: 2 years,
range: 0.1–49). The assessment of secondary ITP in our center included abdominal ultrasound;
peripheral blood smear; testing for HBV, HCV, HIV, H. pylori, and immunoglobulin levels; basic coagulation screen; and antinuclear antibody, antineutrophil
cytoplasmic antibody, antiphospholipid antibodies, and/or bone marrow examination.
Results
Patient Characteristics
A total of 245 patients diagnosed with ITP were identified: 81 men (33.1%) and 164
women (66.9%). The mean follow-up of the whole population was 17.8 months (range:
1 week–138 months). The overall survival of the population was 99.6% (n = 244) during the follow-up. There was one death (0.4%) due to endometrial cancer.
The mean age at diagnosis was 41.3 (median: 40, range: 4–87). In 12.7% of patients
(n = 31), the disease was diagnosed in younger than 18 years. The mean PLT count at
ITP diagnosis was 35.8 × 109/L (median: 30 × 109/L, range: 0–100 × 109/L; see [Table 1]).
Table 1
Patient characteristics and clinical manifestation of ITP
|
Overall
|
Male
|
Female
|
|
n = 245
|
(%)
|
n = 81
|
(%) (33.1)
|
n = 164
|
(%) (66.9)
|
|
Age at ITP diagnosis (years)
|
|
Mean ± SD
|
41.3 ± 20.6
|
–
|
48.7 ± 20.3
|
–
|
38 ± 20
|
–
|
|
Median (range)
|
40 (4–87)
|
–
|
52.5 (4–83)
|
–
|
33 (4–87)
|
–
|
|
PLT count at ITP diagnosis (× 109/L)
Mean ± SD
Median (range)
|
35.8 ± 32.9
30 (0–100)
|
–
|
|
|
|
|
|
Duration of ITP
|
|
• Newly diagnosed (<3 mo after diagnosis)
|
18
|
(7.4)
|
|
|
|
|
|
• Persistent (3–12 mo after diagnosis)
|
38
|
(15.5)
|
|
|
|
|
|
• Chronic (>12 mo after diagnosis)
|
189
|
(77.1)
|
|
|
|
|
|
Primary ITP
|
222
|
(90.6)
|
|
|
|
|
|
Secondary ITP
|
23
|
(9.4)
|
|
|
|
|
|
The circumstances of primary ITP diagnosis
|
|
• Infection
|
27
|
(11.1)
|
|
|
|
|
|
• Pregnancy
|
|
|
|
|
16
|
(9.8)
|
|
The circumstances of ITP diagnosis
|
|
Accidentally
|
140
|
(57.1)
|
45
|
(55.6)
|
95
|
(57.9)
|
|
Symptoms present at diagnosis
|
105
|
(42.9)
|
36
|
(44.4)
|
69
|
(42.1)
|
|
Bleeding symptoms
|
|
Present
|
196
|
(80.0)
|
61
|
(75.3)
|
135
|
(82.3)
|
|
Absent
|
49
|
(20.0)
|
20
|
(24.7)
|
29
|
(21.5)
|
|
• Thrombocytopenic purpura
|
167
|
(68.2)
|
51
|
(63.0)
|
116
|
(70.7)
|
|
• Epistaxis
|
85
|
(34.7)
|
23
|
(28.4)
|
62
|
(37.8)
|
|
• Gum bleeds
|
47
|
(19.2)
|
15
|
(18.5)
|
32
|
(19.5)
|
|
• Bleeding from the genital tract
|
44
|
(18.0)
|
–
|
–
|
44
|
(26.8)
|
|
• Lower gastrointestinal bleeding
|
15
|
(6.1)
|
8
|
(9.9)
|
7
|
(4.3)
|
|
• Hematuria
|
11
|
(4.5)
|
6
|
(7.4)
|
5
|
(3.0)
|
|
• Prolonged bleeding from wounds/subcutaneous hematomas
|
11
|
(4.5)
|
2
|
(2.5)
|
9
|
(5.5)
|
|
• Prolonged bleeding after tooth extraction
|
10
|
(4.1)
|
1
|
(1.2)
|
9
|
(5.5)
|
|
• Postpartum/post-cesarean hemorrhage
|
6
|
(2.4)
|
–
|
–
|
6
|
(3.7)
|
|
• Subconjunctival hemorrhage
|
6
|
(2.4)
|
2
|
(2.5)
|
4
|
(2.4)
|
|
Life-threatening bleeding
|
3
|
(1.2)
|
1
|
(0.4)
|
2
|
(0.8)
|
|
• Intracranial hematoma
|
1
|
(0.4)
|
1
|
(1.2)
|
–
|
–
|
|
• Genital tract bleeding
|
1
|
(0.4)
|
–
|
–
|
1
|
(0.6)
|
|
• Retroperitoneal hemorrhage
|
1
|
(0.4)
|
–
|
–
|
1
|
(0.6)
|
Abbreviations: ITP, immune thrombocytopenia; PLT, platelet.
Among all patients, 90.6% (n = 222) were diagnosed as having primary ITP and 9.4% (n = 23) were diagnosed with secondary ITP. The causes of secondary ITP included the
following: viral hepatitis C (n = 5), cytomegalovirus (CMV) infection (n = 2), H. pylori infection (n = 2), systemic lupus erythematosus (n = 2), rheumatoid arthritis (n = 2), chronic lymphocytic leukemia (n = 2), Evans syndrome (n = 2), primary biliary cholangitis (n = 1), antiphospholipid syndrome (n = 1), human immunodeficiency virus (n = 1), viral hepatitis B (n = 1), coexisting CMV and Epstein–Barr virus infection (n = 1), and alcoholic liver cirrhosis (n = 1). The diagnosis of primary ITP was related to previous infection in 11.1% (n = 27), in particular an infection of the upper respiratory tract.
In 9.8% (n = 16) of female patients, primary ITP was revealed during pregnancy. ITP exacerbations
during pregnancy were reported in 15% of females (n = 26). In all cases, pregnancy-associated thrombocytopenia was excluded (based on
the clinical picture) as well as pregnancy-associated syndromes causing low PLT count.
Twenty-three women (43.4%) required treatment during pregnancy (prednisone: 78.3%,
methylprednisolone: 13.0%, intravenous immunoglobulin [IVIg]: 13.0%, dexamethasone:
4.3%), but only 15 (28.3%) in the postpartum period. No bleeding complications were
noted in the perinatal period. Medical records of 10 newborns were available: 4 presented
with normal PLT count; 2 presented with mild thrombocytopenia, requiring no treatment;
3 were transfused with IVIg; and 1 was transfused with PLT concentrate due to PLT
count < 30.0 × 109/L. None manifested with bleeds.
Patient characteristics and clinical manifestation of ITP according to sex are presented
in [Table 1].
In 42.9% (n = 105) of patients, the diagnosis was preceded by clinical symptoms, whereas the
remaining 57.1% (n = 140) were asymptomatic and diagnosed accidentally during routine follow-up. The
mean PLT count in asymptomatic patients at diagnosis was 45.3 × 109/L (median: 40.0 × 109/L, range: 0–100 × 109/L). The mean PLT count in patients with bleeding at diagnosis was 23.109/L (median: 11.0 × 109/L, range: 0–100 × 109/L). In the course of the disease, symptoms appeared in another 91 patients. Altogether,
80% of patients had bleeding symptoms and 20% remained asymptomatic throughout the
course of the disease. The most common symptom was thrombocytopenic purpura (68.2%;
see [Table 1]). The incidence of life-threatening bleedings was 1.2% (n = 3): intracranial hematoma without previous trauma, retroperitoneal hemorrhage (postovulatory
ovarian hemorrhage), and genital tract bleeding. In the first two cases, major bleeding
was the first symptom of ITP. All three patients had no identifiable bleeding risk
factors besides thrombocytopenia. In the first case, prednisone and intravenous methylprednisolone
were administered which resulted in a rapid, but transient, increase in the PLT count
to a hemostatic level (45.0 × 109/L). Further workup revealed systemic lupus erythematosus and the diagnosis of secondary
ITP was established. Prednisone and chloroquine were ordered with good effect and
the patient remains in outpatient control. The second patient was treated with prednisone
for a total of 5 months after the major bleed. The subsequent splenectomy led to disease
remission with several episodes of thrombocytopenia below 10.0 × 109/L with mild hemorrhagic symptoms during follow-up, treated successfully with short
courses of prednisone. In the third case, major bleeding was observed 15 years after
ITP diagnosis. The patient was treated with prednisone with periodic fluctuations
in the PLT count (20.0–70.0 × 109/L), but treatment tolerance was poor. Currently, she remains untreated in outpatient
control, with PLT count >10.0 × 109/L and no bleeding.
In 14 patients, minor isolated bleeding symptoms occurred despite PLT count > 50.0 × 109/L (easy bruising, mild mucosal bleeds). They could be explained by prolonged steroid
treatment, local pathologies, or concomitant diseases (e.g., hemorrhoids or arterial
hypertension).
Treatment
[Table 2] presents data on ITP treatment. Among all patients, 23.2% (n = 57) did not require therapy (stable asymptomatic disease or spontaneous remission).
The mean value of PLT count at treatment implementation was 12.4 × 109/L (median: 13.0 × 109/L, range: 0–56 × 109/L, number of patients: 188). The median number of therapy lines for the whole cohort
was 1 (range: 0–3). Prednisone was the most commonly used first-line treatment (in
75.5% of the patients; see [Table 2]). An intravenous steroid was administered to 22.9% of the patients. The mean time
of steroid therapy in our clinic was 3.2 months (median: 1.7 months, range: 0.1–37.7
months). In case of using steroids in doses above 20 mg/d of prednisone, the median
time was 1.0 month (median: 0.5, range: 0.1–11 months). A total of 115 patients (61.2%)
who were treated with steroids in our clinic were also treated with steroids before
being admitted to our center. As many as 63.8% of treated patients (120/188) did not
require second-line treatment at all; 38.3% of them (n = 46) achieved complete response (CR) after first-line treatment. Partial response
(PR) was reported in 54.2% (n = 65). The remaining 7.5% (n = 9) were treated by first-line therapy with no effects, but they dropped out of
follow-up. Steroids were used repetitively in the treatment of 84.9% of relapses after
first-time steroid treatment.
Table 2
ITP treatment
|
Treatment
|
Number of patients
|
|
n
|
(%)
|
|
Without treatment
|
57
|
(23.2)
|
|
First-line treatment
|
188
|
(76.7)
|
|
• Prednisone
|
142
|
(75.5)
|
|
• Methylprednisolone
|
38
|
(20.2)
|
|
• Dexamethasone
|
20
|
(10.6)
|
|
• IVIg
|
12
|
(6.4)
|
|
Steroid IV
|
56
|
(22.9)
|
|
Steroid complications
|
51
|
(29.0)
|
|
First-line treatment only
|
120
|
(63.8)
|
|
Second-line treatment
|
68
|
(27.8)
|
|
*Pharmacological treatment
|
47
|
(69.1)
|
|
• Danazol
|
25
|
(53.2)
|
|
• Cyclophosphamide
|
22
|
(46.8)
|
|
• Eltrombopag
Before splenectomy
|
19
10
|
(40.4)
(21.3)
|
|
• Azathioprine
|
14
|
(29.8)
|
|
• Rituximab
|
7
|
(14.9)
|
|
• Romiplostim
Before splenectomy
|
4
1
|
(8.5)
(2.1)
|
|
*Splenectomy
|
35
|
(51.5)
|
|
• As second-line treatment
|
21
|
(60.0)
|
|
• As third-line treatment
|
14
|
(40.0)
|
|
Treatment immediately before splenectomy
|
|
Prednisone
|
11
|
(34.4)
|
|
IVIg
|
8
|
(25.0)
|
|
Methylprednisolone
|
5
|
(15.6)
|
|
Methylprednisolone + IVIg
|
3
|
(9.4)
|
|
Eltrombopag
|
2
|
(6.3)
|
|
Azathioprine
|
1
|
(3.1)
|
|
Romiplostim + prednisone
|
1
|
(3.1)
|
|
Prednisone + azathioprine
|
1
|
(3.1)
|
|
Splenectomy outcome
|
|
No response to splenectomy
|
9
|
(25.7)
|
|
Relapse after splenectomy
|
8
|
(22.9)
|
|
Treatment after relapse
|
|
Eltrombopag
|
6
|
(75.0)
|
|
Prednisone
|
4
|
(50.0)
|
|
Cyclophosphamide
|
4
|
(50.0)
|
|
Methylprednisolone
|
3
|
(37.5)
|
|
Danazol
|
3
|
(37.5)
|
|
Romiplostim
|
2
|
(25.0)
|
|
Dexamethasone
|
1
|
(12.5)
|
|
IVIg
|
1
|
(12.5)
|
Abbreviations: ITP, immune thrombocytopenia; IVIg, intravenous immunoglobulin.
The percentage of patients suffering from steroid adverse events was 29.0% (51 patients).
They included the following: mental disorders from depression to psychosis, steroid-induced
diabetes, osteoporosis with compression fractures, severe bone and muscle pain, headache,
dizziness, cataract, edema, weight gain, and impaired concentration. In 8.5% of cases
(15 patients), they led to therapy change, despite a good PLT response. The median
time between initiation of therapy and adverse event onset was 2 months, ranging from
4 days (blood pressure fluctuations and edema of the lower limbs during a dexamethasone
pulse) to 10 years (edema, bone pain, and steroid-induced osteoporosis). In 27.8%
(n = 68), the second-line treatment was introduced: pharmacological or splenectomy.
The most common second-line therapy was danazol (53.2% of patients). 28% of patients
treated with danazol (n = 7) responded well to treatment (achieved CR or response), whereas in 44% (n = 11) this therapy failed (PLT count < 30 × 109/L). 20% (n = 5) of patients discontinued danazol due to intolerance. Splenectomy was performed
in 51.5% (n = 35) of patients. The percentage of laparoscopic procedures was 88.6% (n = 31), while that of open splenectomies was 11.4% (n = 4). The mean time from ITP diagnosis to splenectomy was 31.9 months (median: 12.0
months, range: 0.5–204 months). The mean value of PLT count at the day of splenectomy
was 57.4 × 109/L (median: 90.0 × 109/L, range: 33–245 × 109/L). Prednisone was the drug that in most cases (34.4%) raised the PLT count to a
level at which splenectomy could be safely performed (see [Table 2]). The mean time of post-splenectomy follow-up was 4.5 years (median: 2 years, range:
2 weeks to 22 years). Nine patients (25.7%) failed to respond to splenectomy at all,
and a further 22.9% (eight patients) relapsed. The mean time from splenectomy to relapse
was 11.3 months (median: 3.5 months, range: 1–60 months). After relapse, the most
common treatment was eltrombopag (in 75% of the patients; see [Table 2]).
Elderly patients (≥ 65 years; n = 37) and pediatric patients (<18 years; n = 31) were analyzed separately (see [Tables 3] and [4]). Among all elderly patients, 18.9% (n = 7) did not require therapy. The mean value of PLT count at treatment implementation
was 19.6 × 109/L (median: 20.0 × 109/L, range: 0–50 × 109/L, number of patients: 30). Twenty-three patients (76.7% of patients who started
treatment) required only first-line therapy. Of those, more than half (52.2%) achieved
CR (PLT count ≥ 100 × 109/L and resolution of bleeding symptoms). In 18.9% (n = 7) of patients, the second-line treatment was introduced: cyclophosphamide (in
4 patients), danazol (in 3 patients), and azathioprine (in 1 patient). Splenectomy
was performed in two patients (5.4%). In response to splenectomy, one patient achieved
complete remission of ITP and did not require further treatment, while the other relapsed
after 1 year and was thereafter ineffectively treated with eltrombopag and finally
achieved complete remission after implementation of prednisone with cyclophosphamide.
Table 3
Elderly patients with ITP (≥ 65 y)
|
Category
|
n
|
(%)
|
|
Number of patients ≥ 65 y
|
37
|
(100)
|
|
Age at ITP diagnosis (years; mean ± SD)
|
73.8 ± 5.9
|
–
|
|
Age at ITP diagnosis (years; median (range))
|
74 (65–87)
|
–
|
|
PLT count at ITP diagnosis (× 109/L): mean ± SD
|
37.0 ± 30.3
|
–
|
|
PLT count at ITP diagnosis (× 109/L): median (range)
|
30 (0–100)
|
–
|
|
Symptoms present at diagnosis
|
14
|
(37.8)
|
|
Bleeding symptoms in the course of ITP
|
26
|
(70.3)
|
|
Without treatment
|
7
|
(18.9)
|
|
First-line treatment
|
30
|
(81.1)
|
|
First-line treatment only
|
23
|
(76.7)
|
|
Complete response after first-line treatment
|
12
|
(52.2)
|
|
Second-line treatment
|
7
|
(18.9)
|
|
Splenectomy
|
2
|
(5.4)
|
Abbreviations: ITP, immune thrombocytopenia; PLT, platelet.
Table 4
Pediatric patients with ITP (<18 y)
|
Category
|
n
|
(%)
|
|
Number of patients < 18 y
|
31
|
(100)
|
|
Age at ITP diagnosis (years; mean ± SD)
|
11.1 ± 4.5
|
–
|
|
Age at ITP diagnosis (years; median (range))
|
10 (4–17)
|
–
|
|
PLT count at ITP diagnosis (× 109/L): mean ± SD
|
31.3 ± 30.0
|
–
|
|
PLT count at ITP diagnosis (× 109/L): median (range)
|
19.5 (1–100)
|
–
|
|
Symptoms present at diagnosis
|
16
|
(51.6)
|
|
Bleeding symptoms in the course of ITP
|
17
|
(54.8)
|
|
Without treatment
|
13
|
(41.9)
|
|
First-line treatment
|
18
|
(58.1)
|
|
First-line treatment only
|
16
|
(88.9)
|
|
Second-line treatment
|
2
|
(6.5)
|
|
Splenectomy
|
1
|
(3.2)
|
Abbreviations: ITP, immune thrombocytopenia; PLT, platelet.
In our group of patients, we identified 31 children (age <18 at the time of ITP diagnosis).
Among all children, 41.9% (n = 13) did not require therapy. The mean value of PLT count at treatment implementation
was 12.109/L (median: 8.5 × 109/L, range: 1–40 × 109/L, number of patients: 18). Sixteen patients (88.9% of patients who started treatment)
required only first-line therapy. The second-line treatment (eltrombopag) was implemented
in two pediatric patients (6.5%): one achieved partial response, and the other did
not respond to therapy. One patient (3.2%) underwent splenectomy, but the disease
relapsed after a month and TPO-RA therapy was initiated. The patient did not respond
either to eltrombopag or to romiplostim (the last measured PLT count was 7 × 109/L, without bleeding symptoms). Of the 13 patients with spontaneous remission observed
in the pediatric period, 6 relapsed in adulthood (46.2%).
Patients requiring anticoagulation were treated based on individual stratification
of bleeding risk (PLT count, bleeding symptoms, and concomitant diseases). We generally
continued full doses of new oral anticoagulants (NOACs) in patients with PLT count
in the range of 50 to 100 × 109/L. In the range of 20 to 50 × 109/L, we individually decided to reduce the NOAC dose by half or discontinue it. In
the PLT range of 0 to 20 × 109/L, NOAC therapy and other oral anticoagulation were avoided because of the high risk
of spontaneous bleeding. Close clinical observation and monitoring of PLT levels were
implemented at each stage of anticoagulant therapy.
Discussion
The studied population consists mainly of chronic ITP patients, referred to our center
for consultation or further treatment. It does not reflect the true distribution of
clinical forms of ITP in the general population. According to literature, 30 to 66.7%
of adults with ITP become chronic (significantly more than in children: 21–25%) and
the rate of spontaneous remissions is 20 to 45%.[10]
[11]
[12]
[13]
[14]
[15]
ITP occurs with an incidence rate of 1.6 to 3.9 per 100,000 person-years, increasing
with age, and has a slight female propensity.[16] In our study, the percentage of males with ITP was 33.1% and that of females was
66.9%. The reported rate of secondary ITP is up to 20%,[2]
[11] whereas in our group 9.4% of patients were diagnosed with an underlying condition.
This observation may indicate that only the minority of secondary cases become chronic
and are therefore underrepresented in our group, or may reflect the selection bias
(secondary ITP patients are less likely to be referred to our center). It may also
suggest that more stress should be put on differential diagnostics and search for
possible causes of secondary ITP.
ITP is asymptomatic in some patients; however, up to two-thirds may experience bleeding
manifestations.[8] Hammond et al described the asymptomatic diagnosis of ITP in 49% of cases.[17] In our study, 80% of patients presented symptoms in the disease course, although
at the moment of diagnosis bleeds were present in only 42.9% of patients.
The risk of bleeding is most significant at PLT counts less than 20 to 30 × 109/L. Bleeding typically occurs in the skin or mucous membranes, with petechiae, bruising,
epistaxis, and gum bleeding being common.[18] ICH occurs in 1.1 to 1.8% of adult ITP patients and usually presents during the
first 3 months after ITP diagnosis.[10]
[19]
[20] In our study, severe life-threatening bleeding was noted in three cases (1.2%),
of which ICH occurred in one patient.
The main goal of ITP treatment is achieving a PLT count that protects against severe
bleeding, rather than keeping it within the normal range. The International Working
Group (IWG) defines CR as PLT count ≥100 × 109/L. Response is defined as PLT count ≥30 but <100 × 109/L and a doubling from baseline. The majority of clinicians use a PLT count of 30 × 109/L as the target threshold of treatment.[21] However, in selected asymptomatic patients, lower thresholds may be kept as a balance
between bleeding risk and treatment toxicity. In our patient group, 6.5% (n = 16) had a chronic history of PLT count below 30 × 109/L. Four of them were left untreated, chronically or temporarily, despite PLT count
of less than 10 × 109/L (due to treatment intolerance or inefficiency). None of these patients presented
with significant bleeds.
Initial treatment of newly diagnosed adults includes several options: corticosteroids
(usually oral prednisone, intravenous methylprednisolone, or oral dexamethasone),
IVIg, and intravenous anti-D immunoglobulins (not available in Poland).[22]
[23] The recommended drug of the first choice is prednisone, administered orally at an
initial dose of 1 mg/kg for 2 to 3 weeks, or dexamethasone 40 mg/d for 4 days, repeated
up to three times.[22] Some studies suggest a higher CR rate with high doses of dexamethasone than with
standard dose of prednisone.[24]
[25]
[26] First-line treatment is effective in 70 to 90% of patients.[23] In most cases, initial treatment will not lead to a sustained increase in PLT count,
however, and as many as 80% of these patients will eventually relapse.[27] Only 10 to 20% of patients achieve sustained response to corticosteroids.[16] Moreover, this group of drugs may cause significant side effects, directly proportional
to the dose and duration of treatment.[16] Steroid dose should therefore be gradually reduced and, in most cases, discontinued.
In the presented group of patients, the most common first-line treatment was oral
prednisone (75.5% of patients) which is in line with Polish and international ITP
treatment guidelines. Dexamethasone was used in 10.6% of patients only, because it
entered the clinical practice only after evidence of its efficacy was published. In
our group, 73.6% of patients could eventually cease steroid therapy. Comparing with
data from the literature, Chang et al described CR to steroids in 65.2% and PR in
23.3% of patients.[28]
Second-line treatment of ITP includes pharmacotherapy and splenectomy. Drugs with
proven effectiveness include eltrombopag, avatrombopag, romiplostim, fostamatinib,
and rituximab, whereas potentially useful agents are azathioprine, cyclosporine A,
cyclophosphamide, danazol, dapsone, mycophenolate mofetil, and vinca alkaloids.[22] Avatrombopag, fostamatinib, and dapsone are not available in Poland.
TPO-RAs: eltrombopag, avatrombopag, and romiplostim increase the number of PLTs by stimulating
their production in the bone marrow. With their excellent efficacy of 60% (regardless
of splenectomy status), eltrombopag and romiplostim have transformed the care of patients
with chronic ITP.[29]
[30]
[31] After treatment cessation, durable responses are observed in 10 to 30% of patients.[13] Both agents were licensed for chronic refractory ITP in adults and children since
1 year of age. Recently, the registration of romiplostim was extended to include adults
with newly diagnosed and persistent ITP. Eltrombopag is reimbursed in Poland since
2018 and romiplostim since 2020, in splenectomized patients only. Unfortunately, high
cost limits their broader use in clinical practice (see [Table 2]).
Rituximab is a chimeric humanized antibody directed against the CD20 surface antigen
of B lymphocytes. Rituximab is useful in patients who have not responded to steroids
or require high doses of steroids to maintain target PLT count.[32]
[33] The literature shows that approximately 60% of ITP patients respond to treatment,
and 20 to 40% achieve complete remission.[14]
[34]
[35]
[36] In some studies, the initial effectiveness of rituximab was as high as 80%.[28] Rituximab is used in ITP treatment off-label, it requires hospitalization in Poland
(due to reimbursement strategy), and its cost was until recently high; this is why
it was rarely administered in the studied group (see [Table 2]).
Immunosuppressants are characterized by variable efficacy, significant side effects,
and delayed onset of action (up to several months). Their use should be limited to
patients failing other therapies, those in whom splenectomy is contraindicated, or
if other agents are unavailable.[22]
Eltrombopag and romiplostim were used in 40.4% (n = 19) and 8.5% (n = 4) of patients, respectively. In 21.3% (n = 10) and 2.1% (n = 1) of patients, respectively, TPO-RAs were used before splenectomy. Due to the
reimbursement policy of TPO-RAs in Poland, nonsplenectomized patients had the chance
to benefit from this therapy only through donations or self-funding. The relatively
common use of eltrombopag in our group results from its availability since 2019 within
a compassionate-managed access program held by Novartis.
[Fig. 1] presents the evolution of pharmacological ITP treatment in our center over the years.
The increase in the use of eltrombopag from 2018 in the second and third lines of
ITP treatment was due to the introduction of TPO-RAs reimbursement in Poland. Single
cases of TPO-RAs treatment before 2018 were short-term therapies in which drugs were
donated by pharmaceutical companies. The increase in cyclophosphamide and danazol
in 2019 can be attributed to the need for preoperative PLT rise (TPO-RAs became at
that time available for splenectomized patients only).
Fig. 1 Time line of distribution of second- and third-line pharmacological treatment (2006-2020).
Splenectomy is an effective therapy for steroid-refractory or steroid-dependent ITP.
For decades, it was positioned as the second-line ITP treatment of choice. Recent
data suggest, however, that nowadays less than 25% of patients with ITP undergo splenectomy,[37] despite an initial response rate of 80% and 5-year response rates of 60 to 70%.[38]
[39]
[40]
[41] With the advent of medical alternatives such as rituximab and TPO-RAs, splenectomy
has declined and it is generally reserved for patients who fail multiple medical therapies.[38] Splenectomy carries the risk of infection as well as a lifelong risk of septic shock
and thrombosis. Fluctuating PLT counts after surgery can be difficult to manage.[13]
[15] Post-splenectomy relapses most often occur within the first 24 months.[42] Following the Polish ITP treatment guidelines, splenectomy may be considered in
patients refractory to corticosteroids for at least 4 to 6 weeks and in patients who
require daily prednisone dose ≥10 mg to maintain the target PLT count.[9]
[23] This recommendation contradicts European guidelines that limit the use of splenectomy
in favor of TPO-RAs. Still, it should be noted that Polish guidelines are dated in
2010 and will be updated soon. In clinical practice, more and more physicians point
to the need to delay splenectomy, favoring repeated pharmacotherapy lines.[43] For several years, physician-driven efforts are made to extend the availability
of TPO-RAs to nonsplenectomized patients with ITP in Poland. [Fig. 2] presents the number of splenectomies per year in our study population. The increase
in the frequency of splenectomies since 2018 was related to the fact that in 2018
the reimbursement of TPO-RAs in splenectomized patients was started in Poland. Patients
with refractory ITP were more readily qualified for splenectomy so that in case of
relapse they could be qualified for TPO-RAs therapy.
Fig. 2 Number of splenectomies per year.
It is recommended to wait for at least 6 months from the diagnosis of ITP to splenectomy
because of spontaneous remissions of the disease observed in some patients.[16] Some authors recommend waiting for 12 months after ITP diagnosis.[21]
[38] In our study, 14.3% (n = 35) of all ITP patients ultimately underwent splenectomy. Of the patients who did
not respond to first-line treatment, 51.5% (n = 35) were enrolled in this procedure. In 60% of them (n = 21), splenectomy was used as second-line therapy, while in 40% (n = 14) it was used as third-line therapy. Data from the literature widely differ in
this respect. In one study, the proportion of ITP patients who underwent splenectomy
was 18.7% and it was most commonly used as third-line therapy[37]; in another study, only 3.6% of ITP patients underwent surgery.[10]
The suggested minimum PLT count for a patient with ITP undergoing splenectomy is ≥30
to 50 × 109/L.[44]
[45] To achieve a safe PLT count, corticosteroids or IVIgs are used.[22] In our study, the mean PLT count during splenectomy was 57.4 × 109/L (median: 90.0 × 109/L, range: 33–245 × 109/L). Platelet count was risen mainly with prednisone (34.4%, n = 11), followed by IVIg (25%, n = 8; see [Table 2]). The initial response rate was obtained in 74.3% of patients (n = 26). Post-splenectomy relapses occurred in 22.9% of patients (n = 8). The rate of post-splenectomy relapses in our study was similar to data from
the literature, reporting a recurrence rate of 20 to 40%.[13]
[17]
[42]
[Fig. 3] presents the current ITP treatment algorithm in our center.
Fig. 3 ITP treatment algorithm in our center.
Conclusions
We characterized a large group of Polish patients with ITP in terms of demographics,
clinical picture, and treatment policy. Drawbacks of our analysis are its retrospective
character and single-center setting. A further limitation of the study is lack of
data on fatigue as one of the main symptoms of ITP.
Our results confirm that ITP is a disorder with heterogenous manifestation and variable
clinical course. Chronic disease often requires multiple treatment lines and balancing
between bleeding risk and treatment toxicity, based on individual risk–benefit assessment.
Drugs with proven efficacy against ITP (TPO-RAs and rituximab) are still not reimbursed
in Poland. Eltrombopag and romiplostim are available only for patients resistant to
splenectomy. Therefore, in our country, second-line ITP treatment is still based on
surgery or immunosuppressants, less effective, and carries higher risk of side effects
than TPO-RAs. Steroid therapy also tends to be prolonged, even despite adverse events.
Additionally, physicians may sometimes decide to perform splenectomy to be able to
qualify refractory patients to effective therapy.[23]
Further efforts should be made to gain access to all approved ITP therapies in Poland.
In particular, an important issue is to increase the share of TPO-RAs in the treatment
of ITP.
